Company Filing History:
Years Active: 2020-2021
Title: Juho Park: Innovator in Cancer Treatment
Introduction
Juho Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of two patents to his name, Park is dedicated to advancing medical science and improving patient outcomes.
Latest Patents
Juho Park's latest patents include a therapeutic agent for treating cancer that comprises an anti-miRNA-albumin composite. This invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which includes an anti-miRNA single-stranded nucleic acid with a sequence complementary to an miRNA sequence. Additionally, the invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate, where serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group. Another significant patent is a tumor cell-specific responsive self-assembling drug nanoconjugate. This drug conjugate acts as a prodrug that is degraded by cathepsin B, which is specifically expressed in tumor tissues, to release doxorubicin. The drug conjugate can form self-assembled nanoparticles and specifically responds to and is activated in tumor cells, thereby minimizing side effects during cancer treatment.
Career Highlights
Juho Park is affiliated with the Korea Institute of Science and Technology, where he conducts his research and development. His work focuses on creating innovative solutions for cancer treatment, showcasing his commitment to improving healthcare.
Collaborations
Some of Juho Park's notable coworkers include Ick Chan Kwon and Kwangmeyung Kim. Their collaborative efforts contribute to the advancement of research in the field of cancer treatment.
Conclusion
Juho Park is a dedicated inventor whose work in cancer treatment is paving the way for innovative medical solutions. His patents reflect a deep understanding of the complexities of cancer and a commitment to enhancing patient care.